Even after the announcement of the suspension of the use of the formula developed by AstraZeneca in more than 9 countries belonging to the European Union (EU), the Undersecretary of Health Promotion and Prevention, Hugo Lopez-Gatell, informed that Mexico will continue with the use of the British vaccine, as the European Medicines Agency (EMA) recently reiterated its support for the anti-COVID dose.

During the press conference on the progress of the pandemic in the country, the official explained that there is no evidence that links the vaccine of the British pharmaceutical company and the University of Oxford with serious effects to the health of an individual or that it causes death. Likewise, it was confirmed that although the vaccines will continue to be used as planned since the mass vaccination campaign began in Mexico, special monitoring will be carried out on the patients to whom they are administered, in addition to considering the study of the events that have arisen in Europe supposedly associated to the immunization with this vaccine.

The official also informed that thanks to the Covax mechanism (COVID-19 Global Access Fund for Vaccines), implemented by the United Nations (UN), Mexico will receive in the next 2 weeks about 2.7 million doses against the coronavirus.

The interruption in the use of the British vaccine was implemented due to reports indicating the formation of blood clots in people immunized with this formula and even hours before Mexico's response to the situation, countries such as Denmark, Norway and Iceland also suspended vaccination with AstraZeneca doses, this time temporarily.

Of the most recent nations to stop the application of the dose, Denmark was the only one to justify its decision publicly, arguing that they took the measure due to a "precautionary principle", in addition to the fact that one of its inhabitants who had already received the vaccine died and a blood clot was detected in the autopsy.

The European Medicines Agency issued today a statement referring to the recently reported events of the AstraZeneca/Oxford dose, assuring that "the benefits of the vaccine continue to outweigh its risks", giving the green light for other nations to continue with its administration, although an evaluation of the diagnosed cases of blood clots will be initiated.

RELATED VIDEO: 5 million CanSino vaccines arrive in Mexico